Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Faldaprevir in Healthy Males
NCT02182362Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2007
- Primary completion
- Feb 2008
- Modality
- Small Molecules, Modified Peptides
01
Overview
Phase 1, randomised, double-blind trial of faldaprevir in hepatitis C (HCV) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with abnormal findings in physical examination at Day 46, Number of patients with clinically relevant changes in vital signs at Day 32 and 4 more. Started May 2007; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02182362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182362.